

**Declaration of Financial/Propriety Interest
2016**

Research/Grants:

National Institutes of Health (NIH)

Consulting (*last three years*):

Xhale, Takeda, Mitsubishi Tanabe Pharma Development America, Taisho Pharmaceutical Inc., Lundbeck, Prismic Pharmaceuticals, Clintara, Total Pain Solutions (TPS), Gerson Lehrman Group (GLG) Healthcare & Biomedical Council

Stockholder:

Xhale, Celgene, Seattle Genetics, Abbvie, Titan Pharmaceuticals, OPKO Health, Inc.

Scientific Advisory Boards:

American Foundation for Suicide Prevention (AFSP), Brain and Behavior Research Foundation (BBRF) (*formerly named National Alliance for Research on Schizophrenia and Depression [NARSAD]*), Xhale, Anxiety, Disorders Association of America (ADAA), Skyland Trail, Clintara. RiverMend Health LLC.

Board of Directors:

AFSP, Gratitude America, ADAA

Income sources or equity of \$10,000 or more:

American Psychiatric Publishing, Xhale, Clintara, CME Outfitters, Takeda

Patents:

Method and devices for transdermal delivery of lithium (*US 6,375,990B1*)

Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (*US 7,148,027B2*)

Speakers Bureau:

None